The FDA approved the second respiratory syncytial virus vaccine for adults 60 and older on May 31.
The vaccine, Pfizer's Abrysvo, is a bivalent shot approved to prevent lower respiratory tract disease caused by RSV, according to a news release from the drugmaker.
GSK received the first approval for an RSV shot May 3 with its Arexvy vaccine.
There are no approved RSV vaccines for children, another population vulnerable to the virus.